Business
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
NEWS RELEASE – REGULATED INFORMATIONDECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
About this update from Mdxhealth Sa
[{"type":"text","content":"NEWS RELEASE – REGULATED INFORMATIONDECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – December 18, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the \"Company\" or \"mdxhealth\"), a commercial-stage precision diagnostics company, today announces the completion of its transition to a single listing on Nasdaq. In accordance with prior announcements made by the Company and the corporate event notice issued by Euronext on December 6, 2023, the last trading day of the Company's ordinary shares (the \"Shares\") on the regulated market of Euronext Brussels was December 15, 2023. Trading of the Shares on Euronext Brussels will not resume and the Shares will, as from today, be de-listed from Euronext and will only be listed and tradeable on Nasdaq. Nothwistanding the above, all Shares, whether or not repositioned to Nasdaq, will continue to be valid Shares with full voting rights, rights to future dividends and other distributions, etc. Furthermore, Shares that have not been repositioned prior to December 15, 2023, the last date that Shares were listed and tradeable on Euronext Brussels, may still be repositioned for trading on Nasdaq at any time after today by contacting the shareholder’s financial intermediary or custodian. For further information and details regarding the transition to a single listing of Shares on Nasdaq and the repositioning process, please visit the dedicated web page on the Company's website (see: Proposed Transition to a Single Listing on NASDAQ - mdxhealth). About mdxhealth® Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at:twitter.com/mdxhealth, facebook.com/mdxhealth and ...